Treatment with Zusduri had a median duration of response of 3.5 years and event-free survival of two years in low-grade ...

IV infiltration and extravasation remind this cancer patient of the constant challenges of speaking up and advocating for ...

Researchers are building on the success of CAR T therapy in blood cancers to explore its use in clear cell renal cell ...

Patients with skin cancer who were fed a high-fiber diet showed better response rates to treatment and longer event-free ...

The FDA's Oncologic Drugs Advisory Committee has casted their votes on the utilization of certain treatments in the multiple ...

After attending several cancer support groups, I reflect on what makes them helpful, inclusive and healing — and invite ...

Personalized cancer vaccines may potentially represent a step forward in guiding the immune system to more precisely target ...

When asked to choose a word other than “survivor” to describe myself, I chose “person” because cancer does not define who I ...

Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how ...

Dr. Ma discussed key findings that have been shared so far this year on the topic of evolving treatment strategies for ...

Dr. Ari Hakimi highlighted how tumor profiling and molecular markers are expanding access to precision-based trials for ...

FDA grants priority review to TAR-200, which demonstrated an 82% complete response in high-risk bladder cancer unresponsive ...